NovoSeven resolved 96.5% of bleeds in haemophilia A or B sufferers
6 December 2016 | By Niamh Louise Marriott, Digital Editor
NovoSeven, a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds demonstrating efficacy with haemophilia...